This is therefore a contrasting of the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation in Allogene Therapeutics Inc. (NASDAQ:ALLO) and Osiris Therapeutics Inc. (NASDAQ:OSIR). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics Inc.	N/A	0.00	211.50M	0.00	0.00
Osiris Therapeutics Inc.	142.82M	4.59	36.53M	0.30	55.69

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Allogene Therapeutics Inc. and Osiris Therapeutics Inc.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Allogene Therapeutics Inc. and Osiris Therapeutics Inc.

	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics Inc.	0.00%	0%	0%
Osiris Therapeutics Inc.	25.58%	15%	7.8%

Liquidity

The Current Ratio of Allogene Therapeutics Inc. is 1.6 while its Quick Ratio stands at 1.6. The Current Ratio of rival Osiris Therapeutics Inc. is 2.2 and its Quick Ratio is has 1.9. Osiris Therapeutics Inc. is better equipped to clear short and long-term obligations than Allogene Therapeutics Inc.

Analyst Recommendations

The Recommendations and Ratings for Allogene Therapeutics Inc. and Osiris Therapeutics Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Allogene Therapeutics Inc.	0	0	2	3.00
Osiris Therapeutics Inc.	0	0	0	0.00

Allogene Therapeutics Inc. has a consensus target price of $45, and a 70.97% upside potential.

Institutional and Insider Ownership

Allogene Therapeutics Inc. and Osiris Therapeutics Inc. has shares held by institutional investors as follows: 52.3% and 25.3%. 21.2% are Allogene Therapeutics Inc.’s share held by insiders. Comparatively, insiders own roughly 52.1% of Osiris Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Allogene Therapeutics Inc.	0.66%	5.31%	4.72%	0%	0%	18.6%
Osiris Therapeutics Inc.	-1.46%	14.94%	41.08%	73.29%	99.18%	25.41%

For the past year Allogene Therapeutics Inc.’s stock price has smaller growth than Osiris Therapeutics Inc.

Summary

On 10 of the 11 factors Osiris Therapeutics Inc. beats Allogene Therapeutics Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects. It markets and distributes its products directly to hospitals, clinics, and physician offices as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.